Key Drivers
- Gross Margin
- Cash Strength
- Operating Losses
AIAI Summary
SUPN is now a broader neuroscience platform via the all-stock Indivior merger, but the investment case hinges on turning roughly $125 million of promised synergies and added scale into durable cash flow—if integration, legal scrutiny, or recent free-cash-flow weakness derail execution, the stock's current valuation leaves little cushion.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Cash Strength
- •Operating Losses
SUPN combines strong gross margins, solid liquidity, and low leverage, but persistent losses, elevated operating expenses, and a weaker latest quarter keep earnings and cash flow under pressure.
Price Behavior
Key Price Behavior Insights:
- •Rebound strength
- •Range resistance
- •Fragile sentiment
SUPN's action over the last month is mixed but improving, with a strong rebound from the early-August selloff and closes back above $48 easing downside pressure, though $48.2–$48.3 is still nearby resistance and a clean uptrend is not yet confirmed.
Sharp drop to $43.25 on 2026-08-04 signals fragile sentiment and pullback risk
Sentiment & News
Key News Insights:
- •Merger Deal
- •Cost Synergies
- •Shareholder Review
Supernus matched Q2 EPS estimates, but the main catalyst was its all-stock merger with Indivior, which would create a larger CNS biopharma company while drawing shareholder fairness scrutiny.
The merger could boost Supernus' scale and efficiency, but investor sentiment may remain cautious until deal valuation and legal questions are resolved
Similar Companies in Healthcare
Other companies in the same sector with AI ratings